Roivant PT raised, H.C. Wainwright touts brepocitinib’s ‘blockbuster potential’ By

On Wednesday, H.C. Wainwright adjusted its outlook on Roivant Sciences (NASDAQ:), increasing the price target to $18.00 from the previous $17.00. The firm has maintained its Buy rating on the company’s shares. The adjustment follows Roivant Sciences’ recent announcements, which include promising developments in its drug pipeline and a strategic buyback of shares.

The company’s drug, brepocitinib, is currently being developed to treat conditions such as NIU and dermatomyositis. H.C. Wainwright’s analyst highlighted brepocitinib’s potential to become a blockbuster drug, a term used for medicines that generate annual sales of at least $1 billion. This potential is a key driver behind the raised price target.

Additionally, Roivant Sciences has made a significant move to repurchase shares held by Sumitomo Pharma. The buyback is valued at $648 million and is expected to reduce the outstanding share count by approximately 9%. This action is seen as a positive step for the company, enhancing shareholder value.

The analyst’s comments underscore the optimism surrounding Roivant Sciences’ prospects. The combined impact of the drug pipeline’s success and the share buyback initiative has contributed to the firm’s decision to revise the price target upward.

Investors and market watchers are keeping a close eye on Roivant Sciences as it progresses with its drug development and strategic financial maneuvers. The increase in the price target reflects confidence in the company’s direction and future performance in the pharmaceutical market.

InvestingPro Insights

In light of H.C. Wainwright’s updated outlook on Roivant Sciences, investors may find additional context through InvestingPro’s real-time data and insights. With a market capitalization of $8.8 billion and a striking revenue growth of 185.76% over the last twelve months as of Q3 2024, Roivant Sciences is showing significant expansion in its financial metrics. Despite a negative gross profit margin of -336.78% in the same period, the company holds a remarkable Return on Assets of 91.49%, indicating efficient management of its assets.

InvestingPro Tips reveal that Roivant Sciences holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations, which could provide financial flexibility for the company’s operations and drug development initiatives. Analysts anticipate sales growth in the current year, aligning with H.C. Wainwright’s positive stance. However, they do not expect the company to be profitable this year, and Roivant Sciences does not pay a dividend to shareholders, which may influence investment strategies focused on income.

For those interested in a deeper dive into Roivant Sciences’ financials and future outlook, there are additional InvestingPro Tips available at To enhance your research experience, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription. This exclusive offer provides access to comprehensive analysis tools and insights to help you make informed investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Original Source Link